Annika Kim Constantino

The stock reaction on Wednesday appeared to be in response to new bipartisan legislation that aims to break up pharmacy benefit managers.

The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

UnitedHealth Group canceled its investor day after reports that the CEO of its insurer unit, Brian Thompson, was fatally shot in Manhattan.

Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

Trump's FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink approved for new studies, company says.

Trump's selection is sounding the alarm in the public health community and leaving the biotech and pharmaceutical industries cautious of changes to come. 

The complaint is the latest move in a bitter legal fight between the U.S.'s three largest so-called pharmacy benefit managers, or PBMs, and the FTC.

Shares of Moderna, Novavax, Pfizer, BioNTech and GSK closed lower on Thursday.

Analysts cited data from a phase one study showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.